Dr. Ankur Bahl

About Doctor

Senior Consultant, Medical Oncology & Haematology Fortis hospitals Dr. Ankur Bahl is a highly accomplished and internationally trained Medical Oncologist with more than 15 years of dedicated experience in diagnosing and treating complex cancers. He is an alumnus of Maulana Azad Medical College (MAMC), New Delhi, where he completed his MBBS and MD in Medicine, followed by his DM in Medical Oncology from the prestigious AIIMS, New Delhi—India’s most renowned medical institution. To further enhance his expertise, Dr. Bahl completed an advanced international course in Adverse Drug Reactions, Drug Interactions & Pharmacovigilance at the University of Oxford, UK, strengthening his command over safe and evidence-based cancer treatment practices. Clinical Expertise Dr. Bahl specializes in:  Immunotherapy for advanced cancers  Targeted therapies combined with chemotherapy  Hormonal therapy for breast and prostate cancers  Supportive & palliative cancer care

Qualification

Awards & Recognitions

Dr. Bahl is widely respected for his scientific research and has served as the lead author for several major Indian real-world studies, including:  Targeted therapy (Cetuximab) in Head & Neck Cancer  Acute Myeloid Leukemia treatment outcomes  Human Papilloma Virus (HPV) prevalence trends in India He is also the founder and driving force behind leading oncology education platforms, organizing evidence-based oncology debates, live tumor boards, masterclasses, and workshops at national and international levels.Professional JourneyBefore joining Fortis Memorial Research Institute (FMRI), Gurugram, Dr. Bahl served as:  Director – Medical Oncology & Haematology Oncology at Max Hospital, Saket  Senior oncology specialist at Rajiv Gandhi Cancer Institute & Research Centre  Faculty member at Maulana Azad Medical College (MAMC) His commitment to patient-centered care, combined with strong academic and clinical achievements, makes Dr. Ankur Bahl one of the most trusted cancer specialists for international patients seeking advanced and safe cancer treatment in India.